MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Colorectal Cancer (CRC). Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with locally advanced mid-low rectal cancer. MRD refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. The study will use a blood-based circulating tumor DNA (ctDNA) methylation test to assess its ability to predict cancer recurrence and survival outcomes. Patients who are newly diagnosed with cT3/N+, M0 mid-low rectal cancer (tumor ≤10 cm from the anal verge) and are eligible for curative-intent treatment will be enrolled. Blood samples will be collected at multiple time points, including before neoadjuvant therapy, before surgery, after surgery, and during follow-up visits over three years. The study will compare MRD status with disease-free survival (DFS), recurrence-free survival (RFS), overall survival (OS), and the time it takes for MRD to detect recurrence compared to standard imaging methods. The goal is to determine whether MRD monitoring can provide an early warning of cancer recurrence and help guide treatment decisions. This study may offer valuable insights into improving postoperative surveillance and personalized treatment strategies for rectal cancer patients.
Detailed description
This is a multicenter, prospective, observational study designed to evaluate the effectiveness of ctDNA-based MRD monitoring in predicting disease recurrence and survival outcomes in patients with locally advanced mid-low rectal cancer. The study will enroll 139 patients who have not previously received chemotherapy, radiotherapy, or targeted therapy.
Key Objectives
Primary Objective:
To explore the correlation between MRD status and disease-free survival (DFS) in locally advanced mid-low rectal cancer patients.
Secondary Objectives:
To assess the relationship between MRD status and 1-year/2-year recurrence-free survival (1yRFS, 2yRFS).
To evaluate the association between MRD status and overall survival (OS).
Exploratory Objectives:
To determine the average time by which MRD detection precedes imaging-based detection of disease recurrence.
To assess the correlation between post-neoadjuvant therapy MRD status and pathological complete response (pCR).
Study Design
Patients will undergo blood sampling at key time points:
Baseline (pre-neoadjuvant therapy) Pre-surgery (0-7 days before surgery) Post-surgery (7±2 days after surgery) Follow-up visits at 1, 3, 6, 9, 12, 18, 24, and 36 months post-surgery MRD status will be assessed using a ctDNA methylation-based PCR test, which provides a rapid, cost-effective alternative to traditional NGS-based methods.
Statistical Analysis Kaplan-Meier survival analysis will be used to estimate DFS, RFS, and OS. Cox proportional hazards models will assess whether MRD status serves as an independent prognostic factor for recurrence.
Multivariate analysis will adjust for clinical variables, including tumor burden and treatment history.
Ethical Considerations The study adheres to the principles of the Declaration of Helsinki and Chinese Good Clinical Practice (GCP) guidelines.
Informed consent will be obtained from all participants, and privacy and confidentiality will be strictly maintained.
Expected Outcomes This study aims to validate the clinical utility of ctDNA-based MRD monitoring in predicting recurrence and survival outcomes for locally advanced mid-low rectal cancer patients. If successful, MRD testing may offer a more effective tool for postoperative surveillance and treatment planning, allowing for earlier interventions and improved long-term outcomes.
Primary outcome measures
- Exploring the correlation between MRD status and disease-free survival (DFS) in patients with locally progressive low and intermediate rectal cancer [Time frame: From surgery to disease recurrence or up to 36 months]
Secondary outcome measures (3)
- Correlation of MRD status with 1-year recurrence-free survival (1yRFS) [Time frame: From surgery to 12 months]
- Correlation of MRD status with 2-year event-free survival (2yRFS) [Time frame: From surgery to 24 months]
- Correlation of MRD status with overall survival (OS) [Time frame: From surgery to death or up to 36 months]
Eligibility criteria
Inclusion criteria
1） Age 18-80 years old, male or female; 2) histologically confirmed diagnosis of rectal adenocarcinoma (i.e., adenoepithelial carcinoma, including adenocarcinoma, mucinous carcinoma, imprinted cell carcinoma, and undifferentiated carcinoma; excluding adenosquamous carcinoma); 3) Preoperative clinical stage cT3 /N+, M0, the lower edge of the tumor is ≤10cm from the anal verge, and no surgical resection is performed; (4) Not receiving chemotherapy, radiotherapy, targeted therapy or other anti-tumor therapy; 5) Radical surgery is available; 6) ECOG score 0-1; 7) Subjects voluntarily enrolled in this study and signed the informed consent, good compliance, follow the planned schedule and actively cooperate with the return to the hospital for regular clinical follow-up and necessary treatment.
Exclusion criteria
- previous other malignant tumors (including non-adenocarcinoma colorectal cancer);
- Previously received other anti-tumor therapy;
- Pregnant and lactating women; (4) Patients with other medical conditions that, in the judgment of the investigator, may interfere with follow-up and short-term survival;
5\) Subjects have other factors that may lead to forced termination of this study, such as other serious illnesses (including mental illness, infectious diseases, fever ≥38℃, etc.) that require combined treatment, serious laboratory test abnormalities, accompanied by family or social factors that will affect the safety of the subjects, or the collection of data and samples.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06879899 · SURVEILLANCE-III